• Molecular NameNafcillin
  • SynonymNafcilina [INN-Spanish]; Nafcillin Sodium; Nafcillin sodium salt; Nafcilline [INN-French]; Nafcillinum [INN-Latin]
  • Weight413.474
  • Drugbank_IDDB00607
  • ACS_NO985-16-0
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)3.17
  • pka2.7
  • LogD (pH=7, predicted)-0.8
  • Solubility (experiment)Soluble
  • LogS (predicted, ACD/Labs)(ph=7)-1.21
  • LogSw (predicted, AB/LogsW2.0)0.13
  • Sw (mg/ml) (predicted, ACD/Labs)0.1
  • No.of HBond Donors2
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds5
  • TPSA121.24
  • StatusFDA approved
  • AdministrationIM, IV
  • PharmacologyA narrow spectrum beta-lactam antibiotic of the penicillin class. As a beta-lactamase-resistant penicillin, it is used to treat infections caused by Gram-positive bacteria, particularly species of staphylococci, that are resistant to other penicillins. Nafcillin is considered therapeutically equivalent to oxacillin, although its safety profile is somewhat different.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability30.0
  • Protein binding89.4
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • Metabollsm<30% hepatic
  • Half life0.5 h
  • ExcretionBiliary and renal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySerious toxicity is unlikely following large doses of nafcillin. Acute ingestion of large doses of nafcillin may cause nausea, vomiting, diarrhea and abdominal pain. Acute oliguric renal failure and hematuria may occur following large doses.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A